Nulojix (belatacept)
- Region
- 🇪🇺 EU
- Active substance
- belatacept
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised
- Therapeutic area
- Graft Rejection; Kidney Transplantation
- CHMP opinion
- Thu 14 Apr 2011
- EU approval
- Fri 17 Jun 2011
- Application
- EMEA/H/C/002098
- ATC
- L04AA28
- Official record
- www.ema.europa.eu
Indication
Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
Regulatory milestones
No milestones recorded in the last year.
Follow Nulojix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.